Amgen Q4 2023 revenue $8.2B (+20% YoY); Non-GAAP EPS $4.71 (+15% YoY)

AMGEN INC

2023-FY EPS reported $12.49 revenue$28,190,000,000

Fourth quarter total revenue $8.2B, up 20% YoY; product sales grew 20% driven by 23% volume growth.
GAAP EPS $1.42, down 53% YoY due to acquisition-related expenses and Horizon costs.
Non-GAAP EPS $4.71, up 15% YoY; full year non-GAAP EPS $18.65, up 5%.
Horizon contributed $954M in product sales Oct 6-Dec 31; nine brands record sales in quarter.
Full year free cash flow $7.4B, down from $8.8B in 2022 due to Horizon expenses and repatriation taxes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

AMGEN INC reported financial results for the fourth quarter and full year 2023.

Period: the fourth quarter and full year 2023
Result: reported results

Exact text from the filing

Fourth Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

AMGEN INC filing history →

Source: SEC EDGAR

accession 0000318154-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.